Sunshine Biopharma Inc Net Assets
Sunshine Biopharma Inc net assets. Based on the latest financial reports, Sunshine Biopharma Inc (SBFM) has net assets worth $27.54 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($33.63 Million) and total liabilities ($6.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Sunshine Biopharma Inc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.54 Million |
| % of Total Assets | 81.88% |
| Annual Growth Rate | 51.26% |
| 5-Year Change | 10784.55% |
| 10-Year Change | N/A |
| Growth Volatility | 3193.31 |
Net Assets of Sunshine Biopharma Inc (2007–2025)
Net assets of Sunshine Biopharma Inc from 2007 to 2025. This chart illustrates how Sunshine Biopharma Inc's net assets have evolved over time, based on quarterly financial data. See Sunshine Biopharma Inc (SBFM) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Sunshine Biopharma Inc (2007–2025)
The table below shows the annual net assets of Sunshine Biopharma Inc from 2007 to 2025. For live market cap and overall valuation, see how much is Sunshine Biopharma Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $23.04 Million | -1.97% |
| 2024-12-31 | $23.50 Million | +10.81% |
| 2023-12-31 | $21.21 Million | -1.94% |
| 2022-12-31 | $21.63 Million | +10117.97% |
| 2021-12-31 | $211.66K | +122.17% |
| 2020-12-31 | $-954.84K | -29.84% |
| 2019-12-31 | $-735.38K | -1219.01% |
| 2018-12-31 | $-55.75K | +90.28% |
| 2017-12-31 | $-573.36K | -173.42% |
| 2016-12-31 | $-209.70K | +64.88% |
| 2015-12-31 | $-597.04K | -54.04% |
| 2014-12-31 | $-387.58K | -4926.98% |
| 2013-12-31 | $-7.71K | -110.95% |
| 2012-12-31 | $70.43K | -31.63% |
| 2011-12-31 | $103.00K | -47.51% |
| 2010-12-31 | $196.22K | +100.63% |
| 2009-12-31 | $97.80K | +652.24% |
| 2008-12-31 | $-17.71K | -232.21% |
| 2007-12-31 | $13.39K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sunshine Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7500200400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Sunshine Biopharma Inc Net Assets Breakdown (December 2025)
Sunshine Biopharma Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.91K | 0.02% |
| Other Comprehensive Income | $-65.31K | -0.28% |
| Other Components | $98.11 Million | 425.87% |
| Total Equity | $23.04 Million | 100.00% |
Sunshine Biopharma Inc Competitors by Market Cap
The table below lists competitors of Sunshine Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Good Shroom Co Inc
V:MUSH
|
$4.11 Million |
|
LDC Dental Public Company Limited
BK:LDC
|
$4.11 Million |
|
Power Line Engineering Public Company Limited
BK:PLE
|
$4.12 Million |
|
Odyssean Investment Trust PLC
LSE:OIT
|
$4.12 Million |
|
Trinitan Metals and Minerals
JK:PURE
|
$4.11 Million |
|
ARGO GOLD INC.
F:P3U
|
$4.11 Million |
|
Bumi Citra Permai Tbk
JK:BCIP
|
$4.11 Million |
|
FUTURE METALS NL
F:3R10
|
$4.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunshine Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,500,754 to 23,038,460, a change of -462,294 (-2.0%).
- Net loss of 5,975,352 reduced equity.
- New share issuances of 1,828,596 increased equity.
- Other comprehensive income increased equity by 764,650.
- Other factors increased equity by 2,919,812.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.98 Million | -25.94% |
| Share Issuances | $1.83 Million | +7.94% |
| Other Comprehensive Income | $764.65K | +3.32% |
| Other Changes | $2.92 Million | +12.67% |
| Total Change | $- | -1.97% |
Book Value vs Market Value Analysis
This analysis compares Sunshine Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | $285.00 | $2.74 | x |
| 2008-12-31 | $-376.81 | $2.74 | x |
| 2009-12-31 | $41.67 | $2.74 | x |
| 2010-12-31 | $1282.48 | $2.74 | x |
| 2011-12-31 | $422.14 | $2.74 | x |
| 2012-12-31 | $274.03 | $2.74 | x |
| 2013-12-31 | $-25.61 | $2.74 | x |
| 2014-12-31 | $-1053.21 | $2.74 | x |
| 2015-12-31 | $-3902.25 | $2.74 | x |
| 2016-12-31 | $-78834.59 | $2.74 | x |
| 2017-12-31 | $-131.41 | $2.74 | x |
| 2018-12-31 | $-36.61 | $2.74 | x |
| 2019-12-31 | $-4154.72 | $2.74 | x |
| 2020-12-31 | $-10975.14 | $2.74 | x |
| 2021-12-31 | $1615.74 | $2.74 | x |
| 2022-12-31 | $28494.82 | $2.74 | x |
| 2023-12-31 | $17425.93 | $2.74 | x |
| 2024-12-31 | $334.89 | $2.74 | x |
| 2025-12-31 | $55.42 | $2.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunshine Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.46%
- • Asset Turnover: 1.21x
- • Equity Multiplier: 1.31x
- Recent ROE (-25.94%) is above the historical average (-421.63%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -97.96% | 0.00% | 0.00x | 1.11x | $-14.46K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.33K |
| 2009 | -25.58% | 0.00% | 0.00x | 1.15x | $-34.80K |
| 2010 | -273.87% | 0.00% | 0.00x | 1.06x | $-557.00K |
| 2011 | -539.99% | 0.00% | 0.00x | 1.03x | $-566.50K |
| 2012 | -1005.24% | 0.00% | 0.00x | 1.91x | $-714.99K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.49 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.90 Million |
| 2015 | 0.00% | -96774.47% | 0.00x | 0.00x | $-1.59 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.48 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-982.90K |
| 2018 | 0.00% | -482.15% | 0.39x | 0.00x | $-2.15 Million |
| 2019 | 0.00% | -7860.85% | 0.22x | 0.00x | $-1.59 Million |
| 2020 | 0.00% | -3898.74% | 0.07x | 0.00x | $-2.69 Million |
| 2021 | -5875.62% | -5444.41% | 0.10x | 10.41x | $-12.46 Million |
| 2022 | -123.66% | -615.44% | 0.15x | 1.37x | $-28.91 Million |
| 2023 | -21.25% | -18.70% | 0.88x | 1.29x | $-6.63 Million |
| 2024 | -21.85% | -14.72% | 1.14x | 1.30x | $-7.48 Million |
| 2025 | -25.94% | -16.46% | 1.21x | 1.31x | $-8.28 Million |
Industry Comparison
This section compares Sunshine Biopharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $86,713,726
- Average return on equity (ROE) among peers: 26.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunshine Biopharma Inc (SBFM) | $27.54 Million | -97.96% | 0.22x | $4.11 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $335.50 Million | -73.41% | 0.53x | $143.73 Million |
| Akanda Corp (AKAN) | $4.28 Million | -95.78% | 0.85x | $584.11K |
| Akebia Ther (AKBA) | $74.01 Million | -330.87% | 6.15x | $194.43 Million |
| Alkermes Plc (ALKS) | $18.84 Million | -398.98% | 9.71x | $7.67 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.25 Billion |
| Amphastar P (AMPH) | $233.44 Million | 7.75% | 0.36x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $5.96 Million | 1208.40% | 615.85x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $135.63 Million | 15.17% | 0.15x | $260.30 Million |
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also … Read more